Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,037 public trials 564 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Active, Not Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235

Conditions
AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +13 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site San Francisco, California, United States
View all 110 locations
View Trial Details
Active, Not Recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Research Site Santa Barbara, California, United States
  • Research Site Aurora, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Minneapolis, Minnesota, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

NCT07150091

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site São Paulo, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
View Trial Details
Active, Not Recruiting

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT04998786

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHR Annecy, France
  • CH de la cote basque Bayonne, France
  • CHRU Hopital Haut Lévêque Bordeaux, France
  • CHU Caen, France
View all 21 locations
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fort Myers, Florida, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Kansas City, Missouri, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Nagoya, Aichi-ken, Japan
  • GSK Investigational Site Kamogawa, Chiba, Japan
  • GSK Investigational Site Kashiwa, Chiba, Japan
  • GSK Investigational Site Matsuyama, Ehime, Japan
View all 13 locations
View Trial Details
Active, Not Recruiting

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321

Conditions
Aging, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations
  • Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • Atrium Health Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States
View Trial Details

Related conditions